Our deep preclinical pipeline includes both autologous and allogeneic therapies.
Adding to our ongoing MAGE-A4 directed autologous program, we are also focusing on the development of a T-cell therapy directed to PRAME - another of the most validated T-cell targets in solid tumors.
We have built one of the leading allogeneic T-cell platforms using human induced pluripotent stem cell lines (hIPSCs). This platform is flexible, scalable, and produces functional T-cells that kill tumor cells in vitro. We will combine this platform with everything we have learned from decades of autologous T-cell therapy research and development into a pipeline for Adaptimmune and its partners for off-the-shelf cell or allogeneic T-cell therapies. We plan to file our first allogeneic IND in 2025.